GALAPAGOS NV/S (NASDAQ:GLPG) – Research analysts at Jefferies Financial Group raised their Q3 2019 earnings per share (EPS) estimates for GALAPAGOS NV/S in a research report issued on Monday, April 29th, Zacks Investment Research reports. Jefferies Financial Group analyst P. Welford now anticipates that the biotechnology company will earn ($1.40) per share for the quarter, up from their prior forecast of ($1.50). Jefferies Financial Group also issued estimates for GALAPAGOS NV/S’s FY2019 earnings at ($4.30) EPS, FY2020 earnings at ($4.40) EPS, FY2021 earnings at ($5.00) EPS, FY2022 earnings at ($5.00) EPS and FY2023 earnings at ($1.00) EPS.
Several other research firms have also recently commented on GLPG. ValuEngine raised shares of GALAPAGOS NV/S from a “buy” rating to a “strong-buy” rating in a research report on Thursday, April 4th. BidaskClub raised shares of GALAPAGOS NV/S from a “sell” rating to a “hold” rating in a research report on Friday, April 5th. HC Wainwright lifted their target price on shares of GALAPAGOS NV/S to $150.00 and gave the stock a “positive” rating in a research report on Friday, March 29th. Cantor Fitzgerald reissued a “buy” rating and set a $130.00 target price on shares of GALAPAGOS NV/S in a research report on Thursday, May 2nd. Finally, Morgan Stanley lifted their price target on shares of GALAPAGOS NV/S from $138.00 to $139.00 and gave the stock an “overweight” rating in a report on Monday, April 29th. Four research analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $127.27.
Large investors have recently bought and sold shares of the stock. We Are One Seven LLC bought a new stake in shares of GALAPAGOS NV/S in the 4th quarter worth approximately $27,000. Wells Fargo & Company MN raised its holdings in shares of GALAPAGOS NV/S by 66.3% in the 1st quarter. Wells Fargo & Company MN now owns 1,678 shares of the biotechnology company’s stock worth $197,000 after purchasing an additional 669 shares during the period. Pinnacle Associates Ltd. bought a new stake in shares of GALAPAGOS NV/S in the 1st quarter worth approximately $231,000. Vestmark Advisory Solutions Inc. bought a new stake in shares of GALAPAGOS NV/S in the 1st quarter worth approximately $252,000. Finally, Financial Gravity Companies Inc. bought a new stake in shares of GALAPAGOS NV/S in the 4th quarter worth approximately $233,000. 15.89% of the stock is currently owned by institutional investors.
About GALAPAGOS NV/S
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.
Read More: What is a bull market?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.